Kelsey Giara, PharmD, RPh

Kelsey Giara is a New Hampshire-based pharmacist and freelance medical writer. She writes about a variety of healthcare topics for various publications with significant experience in continuing medical education, needs assessments and grant writing, and medical communications.

Related

Alzheimer’s & Dementia

FDA Set to Greenlight Monthly Lecanemab Dosing for Alzheimer’s

Kelsey Giara, PharmD, RPh

Monthly, rather than biweekly, dosing could ease medication regimen burden.

Alzheimer’s & Dementia

FDA Set to Greenlight Monthly Lecanemab Dosing for Alzheimer’s

Kelsey Giara, PharmD, RPh

Monthly, rather than biweekly, dosing could ease medication regimen burden.

Pain Management

Suzetrigine’s Pending Approval Signals Shift in Non-Opioid Pain Management

Kelsey Giara, PharmD, RPh

The FDA is expected to decide on the drug’s application on January 30.

Pain Management

Suzetrigine’s Pending Approval Signals Shift in Non-Opioid Pain Management

Kelsey Giara, PharmD, RPh

The FDA is expected to decide on the drug’s application on January 30.

Pulmonary Diseases

Zepbound Approval a First for Obstructive Sleep Apnea

Kelsey Giara, PharmD, RPh

Tirzepatide is the first targeted treatment for OSA, addressing obesity’s underlying impact on disease pathophysiology.

Pulmonary Diseases

Zepbound Approval a First for Obstructive Sleep Apnea

Kelsey Giara, PharmD, RPh

Tirzepatide is the first targeted treatment for OSA, addressing obesity’s underlying impact on disease pathophysiology.

Type 1 Diabetes

FDA Rejects Sotagliflozin for Type 1 Diabetes and CKD

Kelsey Giara, PharmD, RPh

After a previous rejection, the FDA has issued a complete response letter to Lexicon Pharmaceuticals' NDA for sotagliflozin.

Type 1 Diabetes

FDA Rejects Sotagliflozin for Type 1 Diabetes and CKD

Kelsey Giara, PharmD, RPh

After a previous rejection, the FDA has issued a complete response letter to Lexicon Pharmaceuticals' NDA for sotagliflozin.

Nemolizumab is the First IL-31 Inhibitor for Eczema

Kelsey Giara, PharmD, RPh

Two new biologics for eczema target different cytokines and symptoms, offering individualized treatment options.

Nemolizumab is the First IL-31 Inhibitor for Eczema

Kelsey Giara, PharmD, RPh

Two new biologics for eczema target different cytokines and symptoms, offering individualized treatment options.

Infectious Diseases

What’s new in antibiotics?

Kelsey Giara, PharmD, RPh

While the general antibiotic development pipeline is lacking, recent discoveries could aid in the fight against antimicrobial resistance.

Infectious Diseases

What’s new in antibiotics?

Kelsey Giara, PharmD, RPh

While the general antibiotic development pipeline is lacking, recent discoveries could aid in the fight against antimicrobial resistance.

Pulmonary Diseases

Why is the FDA considering a change to OTC decongestants?

Kelsey Giara, PharmD, RPh

Kelsey Giara, PharmD, RPh, explains the recent FDA proposal.

Pulmonary Diseases

Why is the FDA considering a change to OTC decongestants?

Kelsey Giara, PharmD, RPh

Kelsey Giara, PharmD, RPh, explains the recent FDA proposal.

Infectious Diseases

FDA Expands Indication for RSV Vaccines

Kelsey Giara, PharmD, RPh

Arexvy now indicated for high-risk adults from age 50 onward, while Abrysvo is indicated in those 18 and older.

Infectious Diseases

FDA Expands Indication for RSV Vaccines

Kelsey Giara, PharmD, RPh

Arexvy now indicated for high-risk adults from age 50 onward, while Abrysvo is indicated in those 18 and older.

Infectious Diseases

FDA Approves Moderna’s RSV Vaccine

Kelsey Giara, PharmD, RPh

Vaccine is the first and only to use mRNA technology. Decision on GSK’s Arexvy’s extended indication for RSV is still outstanding.

Infectious Diseases

FDA Approves Moderna’s RSV Vaccine

Kelsey Giara, PharmD, RPh

Vaccine is the first and only to use mRNA technology. Decision on GSK’s Arexvy’s extended indication for RSV is still outstanding.

Pulmonary Diseases

FDA Approves Dupixent as First Biologic for COPD Maintenance

Kelsey Giara, PharmD, RPh

Interleukin inhibitor shown to reduce COPD exacerbations in adults with uncontrolled disease.

Pulmonary Diseases

FDA Approves Dupixent as First Biologic for COPD Maintenance

Kelsey Giara, PharmD, RPh

Interleukin inhibitor shown to reduce COPD exacerbations in adults with uncontrolled disease.

Medication Management

What should I know about the latest Beers Criteria for medication use in older adults?

Kelsey Giara, PharmD, RPh

Key changes affect SGLT2 inhibitors, low-dose doxepin, and PPIs.

Medication Management

What should I know about the latest Beers Criteria for medication use in older adults?

Kelsey Giara, PharmD, RPh

Key changes affect SGLT2 inhibitors, low-dose doxepin, and PPIs.

Gastrointestinal Disorders

FDA Expands Guselkumab’s Indication for Treatment of Ulcerative Colitis

Kelsey Giara, PharmD, RPh

FDA approval of guselkumab’s supplemental Biologics License Application for moderately to severely active UC was supported by data from the Phase 2b/3 QUASAR program.

Gastrointestinal Disorders

FDA Expands Guselkumab’s Indication for Treatment of Ulcerative Colitis

Kelsey Giara, PharmD, RPh

FDA approval of guselkumab’s supplemental Biologics License Application for moderately to severely active UC was supported by data from the Phase 2b/3 QUASAR program.